<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706924</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-VM1500FDC-01</org_study_id>
    <nct_id>NCT03706924</nct_id>
  </id_info>
  <brief_title>Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects</brief_title>
  <official_title>Open-Label, Randomized, Parallel-group, Comparative Study of Pharmacokinetics and Bioequivalence of VM-1500FDC (Viriom Ltd, Russia) and Elpida® (Viriom Ltd, Russia) and Truvada® (Gilead Sciences Ireland UC, UK) When сo-administrated Once Daily Fasting in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viriom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viriom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, randomized, parallel-group, comparative study of pharmacokinetics and&#xD;
      bioequivalence of VM-1500FDC (elsulfavirine/emtricitabine/tenofovir fixed-dose combination)&#xD;
      and Elpida® with Truvada® (emtricitabine/tenofovir) co-administered by healthy male subjects.&#xD;
      The study will also assess safety profile of study drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study assesses PK and bioequivalence of the developed new drug VM-1500FDC - a fixed&#xD;
      combination of three active substances: elsulfavirine (NNRTI), emtricitabine (NRTI) and&#xD;
      tenofovir (NRTI) to Elpida® and Truvada® co-administered. The combination is intended for&#xD;
      once daily administration (1 tablet) for the treatment of HIV-1 infection in adult patients.&#xD;
      Thus, the purpose of this combination is to simplify the dosage regimen and improve patient&#xD;
      compliance&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">October 12, 2018</completion_date>
  <primary_completion_date type="Actual">October 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of VM1500A</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of elsulfavirine</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of emtricitabine</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of tenofovir</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of AEs and SAEs</measure>
    <time_frame>29 days</time_frame>
    <description>Frequency and severity of AE, recorded after administration of the drug according to subjective complaints, changes in vital signs, ECG, laboratory results and physical examination compared to the baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>VM-1500FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elpida® &amp; Truvada®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VM-1500FDC</intervention_name>
    <description>A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets</description>
    <arm_group_label>VM-1500FDC</arm_group_label>
    <other_name>VM1500FDC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elpida®</intervention_name>
    <description>Elpida®, capsules, elsulfavirine 20 mg</description>
    <arm_group_label>Elpida® &amp; Truvada®</arm_group_label>
    <other_name>VM-1500</other_name>
    <other_name>VM1500</other_name>
    <other_name>Elsulfavirine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada®</intervention_name>
    <description>Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets</description>
    <arm_group_label>Elpida® &amp; Truvada®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-smoking male subjects between the ages of 20 and 40 years (inclusive);&#xD;
&#xD;
          2. Verified diagnosis of &quot;healthy&quot; according to standard clinical, laboratory and&#xD;
             instrumental examination methods;&#xD;
&#xD;
          3. Body weight from 60 to 95 kg and Body Mass Index from 19.0 to 27.0 kg/m;&#xD;
&#xD;
          4. A negative result in tests for alcohol and drugs;&#xD;
&#xD;
          5. The subject's consent to use adequate contraception methods during the study and 3&#xD;
             month after end of study: condom with spermicide (foam, gel, cream, suppositories);&#xD;
&#xD;
          6. Signed the Participant Explanation Sheet and the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal&#xD;
             system, as well as diseases of the gastrointestinal tract, liver, kidneys, blood;&#xD;
&#xD;
          2. Variables of standard laboratory and instrumental parameters are beyond the normal&#xD;
             limits Variables of standard laboratory and instrumental parameters are beyond the&#xD;
             normal limits (taking into account the acceptable limits of laboratory parameters);&#xD;
&#xD;
          3. Surgical interventions on the gastrointestinal tract in medical history (except&#xD;
             appendectomy);&#xD;
&#xD;
          4. Systolic pressure less than 90 mm Mercury or above 130 mm Mercury, diastolic pressure&#xD;
             less than 60 mm Mercury or above 85 mm Mercury, heart rate less than 60 BPM or more&#xD;
             than 90 BPM at screening;&#xD;
&#xD;
          5. Regular intake of drugs less than 2 weeks prior to screening (including herbal&#xD;
             preparations and dietary supplements); intake of drugs that have a pronounced effect&#xD;
             on hemodynamics, liver function, etc. (for example, barbiturates, omeprazole,&#xD;
             cimetidine, etc.) less than 30 days prior to screening;&#xD;
&#xD;
          6. Presence of antibodies to HIV and hepatitis C virus, presence of hepatitis В surface&#xD;
             antigen, a positive syphilis test;&#xD;
&#xD;
          7. An unstable sleep structure (e.g., night work, sleep disorders, insomnia, recent&#xD;
             return from another time zone, etc.), extreme physical activity (e.g. weight lifting),&#xD;
             a special diet (e.g. vegetarian, vegan);&#xD;
&#xD;
          8. Signs of alcohol (taking more than 10 units of alcohol per week ) or drug addiction;&#xD;
             alcohol or drugs consumption within 4 days prior to screening; cigarettes smoking 3&#xD;
             months prior to screening; positive drug and/or alcohol test;&#xD;
&#xD;
          9. Burdened allergic medical history (including drug intolerance and food allergy);&#xD;
&#xD;
         10. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;&#xD;
&#xD;
         11. Hypersensitivity to tenofovir, elsulfavirine or emtricitabine, as well as any other&#xD;
             component of the study drugs;&#xD;
&#xD;
         12. Blood/plasma donation (450 ml of blood or plasma and more) less than 2 months prior to&#xD;
             screening;&#xD;
&#xD;
         13. Treatment with a study drug in framework of other clinical trials within 30 days prior&#xD;
             to screening (including follow-up visits);&#xD;
&#xD;
         14. Acute infectious diseases less than 4 weeks prior to screening;&#xD;
&#xD;
         15. Incapable of reading or writing; no desire to understand and adhere to the study&#xD;
             protocol procedures; non-compliance with the drugs intake regimen or execution of&#xD;
             procedures, which as the Investigator may think may affect the study results or&#xD;
             subject's safety and prevent the subject from further participation in the study; any&#xD;
             other associated medical or serious psychological conditions making the subject not&#xD;
             eligible to participate in the clinical study, restricting legality of obtaining the&#xD;
             informed consent or affecting the subject's ability to take part in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Mazygula, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private non - governmental health care institution &quot;Scientific Clinical Center of the open joint - stock company Russian Railways&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central City Clinical Hospital Reutov</name>
      <address>
        <city>Reutov</city>
        <state>Moscow Region</state>
        <zip>143965</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private non - governmental health care institution &quot;Scientific Clinical Center of the open joint - stock company Russian Railways&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV -1</keyword>
  <keyword>elsulfavirine fixed-dose combination</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Elsulfavirine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

